Precision Medicine Market The National Cancer Institute (NCI) runs the NCI-COG Pediatric MATCH trial, which enrols children and adolescents in advanced cancer therapy based on their genetic abnormality. NCI also plans to fund new immunotherapy clinical trials, antibody testing, cell, small molecule, and radiation therapy studies, as well as tumour specimen sequencing. The National Cancer Institute (NCI) also launched a number of precision medicine trials in July 2017, including ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials), Lung Cancer Master Protocol (Lung-MAP), NCI-MATCH (Molecular Analysis for Therapy Choice), and Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT).
The global precision medicine market is segmented by technology and application in this analysis. Bioinformatics, gene sequencing, drug discovery, precision molecular diagnostics, and big data analytics are the technology segments of the global precision medicine market. Precision medicine has applications in oncology, CNS, haematology, respiratory medicine, and immunology, among others.
Global Precision Medicine Market Segmentation Forecast: Bioinformatics, Gene Sequencing, Drug Discovery, Precision Molecular Diagnostics, and Big Data Analytics are the technologies that make up the global precision medicine market.
By Application, the is segmented into the following segments:
Oncology, Breast Cancer, Lung Cancer, and Other Cancers
CNS,Hematology,Respiratory,Immunology,Others,.
Precision medicine is also showing promise in the treatment of cancer, cardiovascular illness, psychiatric disorders, neurodegenerative diseases, arthritis, obesity, diabetes, pain, and Alzheimer’s disease. Precision medicine draws patients because it reduces the cost of therapy by eliminating most of the pricey treatments that aren’t necessary since genetic testing enables oncologists to provide precision medicine.
The following are the study’s main features:
This study provides an in-depth analysis of precision medicine in the medical sector, as well as market size (in millions of dollars) and CAGR percent for the projected period (2016–2024), using 2015 as the base year.
It illustrates the attractive investment proposition matrix for this industry and elucidates prospective revenue opportunities across several categories.
This research also includes information on market drivers, restraints, opportunities, product pipelines, regional outlooks, and competitive strategies used by the top competitors.
It profiles the global precision medicine market’s top players based on the following criteria: business overview, financial performance, product portfolio, geographic presence, distribution tactics, important advancements and strategies, and future plans.
Marketers and company executives will be able to make informed decisions based on the findings of this research when it comes to future product launches, technology upgrades, market expansion, and marketing approaches.
The following are some of the market’s major players:
Novartis AG is a pharmaceutical company based in Switzerland.
Intomics.
Incode Ferrer.
Nanostring Technologies, Inc. is a company that develops nanostrings.
Pfizer, Inc. is a pharmaceutical company.
Teva Pharmaceuticals is a pharmaceutical company based in Israel.
Merck & Co., Inc. is a pharmaceutical company based in New Jersey.
Qiagen N.V. is a company based in the Netherlands.
Quest Diagnostics is a company that specialises in diagnostic testing.
